## or BRADY

## Brady Corporation F'21 Q3 Financial Results

May 20, 2021

## Forward-Looking Statements

In this presentation, statements that are not reported financial results or other historic information are "forward-looking statements." These forward-looking statements relate to, among other things, the Company's future financial position, business strategy, targets, projected sales, costs, earnings, capital expenditures, debt levels and cash flows, and plans and objectives of management for future operations.

The use of words such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "should," "project," "continue" or "plan" or similar terminology are generally intended to identify forward-looking statements. These forward-looking statements by their nature address matters that are, to different degrees, uncertain and are subject to risks, assumptions, and other factors, some of which are beyond Brady's control, that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. For Brady, uncertainties arise from: adverse impacts of the novel coronavirus ("COVID-19") pandemic or other pandemics; decreased demand for our products; our ability to compete effectively or to successfully execute our strategy; Brady's ability to develop technologically advanced products that meet customer demands; raw material and other cost increases; difficulties in protecting our websites, networks, and systems against security breaches; extensive regulations by U.S. and non-U.S. governmental and self-regulatory entities; risks associated with the loss of key employees; divestitures and contingent liabilities from divestitures; Brady's ability to properly identify, integrate, and grow acquired companies; litigation, including product liability claims; foreign currency fluctuations; potential write-offs of Brady's goodwill and other intangible assets; changes in tax legislation and tax rates; differing interests of voting and non-voting shareholders; numerous other matters of national, regional and global scale, including major public health issues and those of a political, economic, business, competitive, and regulatory nature contained from time to time in Brady's U.S. Securities and Exchange Commission filings, including, but not limited to, those factors listed in the "Risk Factors" section within Item 1A of Part I of Brady's Form 10-K for the year ended July 31, 2020 and subsequent Form 10-Q filings.

These uncertainties may cause Brady's actual future results to be materially different than those expressed in its forward-looking statements. Brady does not undertake to update its forward-looking statements except as required by law.

## Tender Offer for Nordic ID Oyj

## Nordic ID Overview:

- Finnish publicly-traded company.
- Anticipated purchase price of approximately USD 13M.
- Nordic ID has a complete range of RFID readers, scanners, and the associated software platform.


## Strategic Rationale:

- The acquisition of Nordic ID provides a complementary product offering and helps complete Brady's RFID product offering.
- Nordic ID's technology, combined with Brady's leading market position in niche application industrial printers and materials make this an attractive combination to accelerate growth in industrial track-and-trace applications.



RFID Antennas


RFID Enhancements


Handheld Readers

nordic" id

## Q3 F'21 Financial Summary

- Sales were $\$ 295.5 \mathrm{M}$ in Q3 of F'21 compared with $\$ 265.9 \mathrm{M}$ in Q3 of F'20.
- Organic sales grew $6.5 \%$ and foreign currency translation increased sales 4.6\%.
- Gross profit margin of $50.4 \%$ in Q3 of F'21 compared with $48.7 \%$ in Q3 of F'20.
- SG\&A expense of \$90.8M (30.7\% of sales) in Q3 of F'21 compared with \$83.2M (31.3\% of sales) in Q3 of F'20.
- R\&D expense of \$11.3M (3.8\% of sales) in Q3 of F'21 compared with \$9.8M (3.7\% of sales) in Q3 of F'20.
- Income before income taxes and losses of unconsolidated affiliate increased 116\% to $\$ 47.8 \mathrm{M}$ in Q3 of F'21 compared with $\$ 22.2 \mathrm{M}$ in Q3 of F'20.
- Q3 of F'20 income before income taxes includes $\$ 13.8 \mathrm{M}$ of non-cash impairment charges.
- Net income per Class A Diluted Nonvoting Common Share was $\$ 0.71$ in Q3 of F'21 compared with \$0.26 in Q3 of F'20.
- Q3 of F'20 diluted EPS includes $\$ 0.21$ of non-cash impairment charges and a higher-thannormal tax rate of $38.5 \%$.
- Net cash provided by operating activities increased $30.9 \%$ to $\$ 56.0 \mathrm{M}$ in Q3 of F'21 compared to \$42.8M in Q3 of F'20.


## Sales Overview

SALES


## Q3 F'21 SALES:

- Total sales increased 11.1\%.
- Organic sales increased 6.5\%:
- ID Solutions - Organic sales increase of 9.8\%.
- Workplace Safety - Organic sales decline of 2.2\%.
- $4.6 \%$ increase due to foreign currency translation.


## Q3 F'21 SALES COMMENTARY:

- ID Solutions - Organic sales continued to show sequential improvement in Q3 of F'21 and returned to year-over-year organic growth.
- Workplace Safety - Organic sales decline primarily due to strong comparables due to the sale of Covidrelated products in the prior year.


## Gross Profit Margin

GROSS PROFIT \& GPM\%


## Q3 F'21 - GROSS PROFIT MARGIN:

- Gross profit margin of $50.4 \%$ compared to $48.7 \%$ in Q3 of F'20.
- We continue to invest in automation and manufacturing efficiencies.
- Efficiency gains, automation and selected price increases more than offset the negative impacts caused by input-cost inflation, product mix, and reduced sales volumes in our Workplace Safety business.


## SG\&A Expense

SG\&A EXPENSE AND SG\&A EXPENSE AS A \% of SALES


## Q3 F'21 - SG\&A EXPENSE:

- SG\&A expense decreased as a percent of sales due to ongoing benefits from efficiency actions and increased sales more than offsetting increased compensation and foreign currency translation.
- Sequentially, SG\&A expense was up $\$ 8.6 \mathrm{M}$ compared to the second quarter of this year. This increase was primarily due to incremental investments in sales-generating resources, incentive-based compensation, and foreign currency.


## R\&D Expense

R\&D EXPENSE AND R\&D EXPENSE AS A \% of SALES
(millions of USD)


## Q3 F'21 - R\&D EXPENSE:

- We continue to invest in R\&D to drive future organic sales growth.
- Solid new product pipeline.
- Focused on ensuring our R\&D spend is both efficient and effective.


## Income Before Income Taxes

INCOME BEFORE INCOME TAXES AND LOSSES OF UNCONSOLIDATED AFFILIATE (millions of USD)


## Q3 F'21 - INCOME BEFORE INCOME TAXES AND LOSSES OF UNCONSOLIDATED AFFILIATE:

- Income before income taxes and losses of unconsolidated affiliate increased 115.7\% to \$47.8M in Q3 of F'21 compared to $\$ 22.2 \mathrm{M}$ in Q3 of F'20.
- Q3 of F'20 income before income taxes was negatively impacted by $\$ 13.8 \mathrm{M}$ of non-cash impairment charges.


## Net Income \& Diluted EPS

NET INCOME PER CLASS A DILUTED SHARE


NET INCOME
(millions of USD)


## Q3 F'21 - NET INCOME \& DILUTED EPS:

- Net income was $\$ 37.3 \mathrm{M}$ in Q3 of F'21 compared to $\$ 13.6 \mathrm{M}$ in Q3 of F'20.
- Diluted EPS was $\$ 0.71$ in Q3 of F'21 compared to $\$ 0.26$ in Q3 of F'20.
- Q3 F'20 net income and diluted EPS were negatively impacted by the following:
- $\$ 13.8 \mathrm{M}$ of impairment charges (\$11.1M after tax).
- Higher-than-normal income tax rate of $38.5 \%$ primarily due to an increase in valuation allowances against foreign tax credit carryforwards.


## Cash Generation \& Uses



## CASH FLOWS IN Q3 OF F'21:

- Cash flow from operating activities was $\$ 56.0 \mathrm{M}$ in Q3 of F'21 compared to $\$ 42.8 \mathrm{M}$ in Q3 of $\mathrm{F}^{\prime} 20$.
- Free cash flow* was $\$ 49.1 \mathrm{M}$ in Q3 of F'21 compared to $\$ 34.3 \mathrm{M}$ in Q3 of F'20.
- We returned $\$ 11.5 \mathrm{M}$ to our shareholders in the form of dividends in Q3 of F'21.
- Cash generation continues to be robust and in excess of reported net income.

| (millions of USD) | 3 Mos. Ended <br> Apr. 30, 2021 |  | 3 Mos. Ended Apr. 30, 2020 |  | 9 Mos. Ended <br> Apr. 30, 2021 |  | 9 Mos. Ended Apr. 30, 2020 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cash Balance - Beginning of Period | \$ | 277.6 | \$ | 289.8 | \$ | 217.6 | \$ | 279.1 |
| Cash Flow from Operating Activities |  | 56.0 |  | 42.8 |  | 154.9 |  | 95.9 |
| Capital Expenditures |  | (6.9) |  | (8.5) |  | (21.4) |  | (21.6) |
| Dividends |  | (11.5) |  | (11.3) |  | (34.3) |  | (34.4) |
| Share Repurchases |  | - |  | (64.1) |  | (3.6) |  | (64.1) |
| Effect of Exchange Rates on Cash |  | 1.1 |  | (9.2) |  | 7.4 |  | (9.0) |
| Other |  | 5.5 |  | (0.6) |  | 1.2 |  | (7.0) |
| Cash Balance - End of Period | \$ | 321.8 | \$ | 238.9 | \$ | 321.8 | \$ | 238.9 |

Free Cash Flow is calculated as Net Cash Provided by Operating Activities less Capital Expenditures.

## Net Cash

## NET CASH



## STRONG BALANCE SHEET:

- April 30, 2021 cash $=\$ 321.8 \mathrm{M}$.
- Brady has no outstanding debt.
- Balance sheet provides flexibility for future organic and inorganic investments.


## F'21 Diluted EPS Guidance

Diluted EPS Guidance for the
Year Ending July 31, 2021
\$2.58 to \$2.68

Implied Diluted EPS Guidance for
\$0.64 to \$0.74
Q4 of F'21 (compares to $\$ 0.53$ in Q4 of $F^{\prime 20)}$

Guidance Assumptions:

- Continued economic improvement and the successful roll-out of vaccines around the globe.
- Low-teens organic sales growth in Q4 of F'21.


## Identification Solutions

| Q3 F'21 vs. Q3 F |  | (millions of USD) |  |
| :---: | :---: | :---: | :---: |
|  | Q3 F'21 | Q3 F'20 | Change |
| Sales | \$ 218.1 | \$ 193.2 | + 12.9\% |
| Segment Profit | 47.5 | 36.4 | + 30.6\% |
| Segment Profit \% | 21.8\% | 18.8\% | + 300 bps |

SALES \& SEGMENT PROFIT \% (millions of USD)


Organic
Growth
5.7\% 3.6\% $4.0 \% \quad 3.3 \% ~(0.2 \%)(1.3 \%)(8.2 \%)(21.7 \%)(8.4 \%)(6.9 \%) 9.8 \%$

## Q3 F'21 SUMMARY:

- Revenues increased 12.9\%:
- Organic growth $=+9.8 \%$.
- $\mathrm{Fx}=+3.1 \%$.
- Organic sales growth in all regions.
- Expenses are well controlled due to sustainable efficiency activities as well as cost containment activities.
- Segment profit as a percent of sales increased even though we have increased our innovation investments and are actively investing in salesgenerating resources.


## OUTLOOK:

- Improving market conditions.
- Anticipate strong organic sales growth in Q4 of F'21.
- Continued strong profitability and cash generation.


## Workplace Safety

Q3 F'21 vs. Q3 F'20
(millions of USD)

|  | Q3 F'21 | Q3 F'20 | Change |
| :--- | ---: | ---: | :---: |
| Sales | $\$ 77.4$ | $\$ 72.8$ | $+6.4 \%$ |
| Segment Profit | 5.7 | 4.4 | $+29.2 \%$ |
| Segment Profit \% | $7.3 \%$ | $6.0 \%$ | +130 bps |

SALES \& SEGMENT PROFIT \%
(millions of USD)


[^0]
## Q3 F'21 SUMMARY:

- Revenues increased 6.4\%:
- Organic sales declined 2.2\%.
- $\mathrm{Fx}=+8.6 \%$.
- Organic sales declined due to the North American business and Australia.
- Europe experienced low-single digit organic sales growth in the quarter.
- Segment profit increased due to the increased sales levels in the current year along with costs incurred in the prior year to address our cost structure.


## OUTLOOK:

- Challenging comparables in Q4 of F'21 due to strong Covid-related product sales in the prior year.
- Anticipate a continued slowdown in Covid-related product sales to be partially offset by increased core product sales.
- Anticipate organic sales to decline in Q4 of F'21.


## Investor Relations

## Brady Contact:

Ann Thornton
Investor Relations 414-438-6887

Ann_Thornton@bradycorp.com

See our web site at www.bradycorp.com/investors

## BRC <br> Listed <br>  <br> wumbradycerpom


[^0]:    $\begin{array}{llllllllll} & \begin{array}{lllllll}\text { Organic } \\ \text { Growth }\end{array} \text { 2.2\% } & (0.9 \%) & (1.6 \%) & (2.6 \%) & (0.8 \%) & (1.0 \%) & 0.2 \% & 10.8 \% & 5.5 \%\end{array}(4.8 \%)(2.2 \%)$

